BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35031634)

  • 1. Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer.
    Hsu JY; Chang CJ; Cheng JS
    Sci Rep; 2022 Jan; 12(1):729. PubMed ID: 35031634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Li CH; Karantza V; Aktan G; Lala M
    Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum-containing regimens for metastatic breast cancer.
    Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
    Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
    Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer.
    Srimuninnimit V; Pornpraserthsuk P; Chaiwerawattana A; Kongdan Y; Namkanisorn T; Somwangprasert A; Jatuparisuthi C; Puttawibul P; Vongsaisuwan M; Thongthieang L; Bandidwattanawong C; Tantimongkolsuk C
    PLoS One; 2018; 13(12):e0209040. PubMed ID: 30566471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Web-based Prediction Model for Early Death in Patients With Metastatic Triple-negative Breast Cancer.
    Pan WK; Ren SY; Zhu LX; Lin BC
    Am J Clin Oncol; 2024 Feb; 47(2):71-80. PubMed ID: 37871164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.
    Zhang J; Wang L; Wang Z; Hu X; Wang B; Cao J; Lv F; Zhen C; Zhang S; Shao Z
    Cancer Biol Ther; 2015; 16(2):225-32. PubMed ID: 25648299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum-containing regimens for triple-negative metastatic breast cancer.
    Egger SJ; Chan MMK; Luo Q; Wilcken N
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013750. PubMed ID: 33084020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple-negative breast cancer.
    Aly A; Shah R; Hill K; Botteman MF
    Future Oncol; 2019 Mar; 15(9):1007-1020. PubMed ID: 30717602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
    Tzikas AK; Nemes S; Linderholm BK
    Breast Cancer Res Treat; 2020 Aug; 182(3):643-654. PubMed ID: 32524352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach.
    Kim H; Kim HJ; Kim H; Kim HR; Jo H; Hong J; Kim R; Kim JY; Ahn JS; Im YH; Lee SK; Kim H; Shin SY; Park YH
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-associated survival outcomes in real-world patients with de novo metastatic triple-negative breast cancer: Age as a significant treatment effect-modifier.
    Chung WP; Yang CT; Chen HY; Su CY; Su HW; Ou HT
    J Formos Med Assoc; 2022 Jan; 121(1 Pt 2):319-328. PubMed ID: 34006465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment
    Gong C; Ma G; Hu X; Zhang Y; Wang Z; Zhang J; Zhao Y; Li Y; Xie Y; Yang Z; Wang B
    Oncologist; 2018 Oct; 23(10):1144-1152. PubMed ID: 30082489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
    Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
    Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic therapy, survival and end-of-life costs for metastatic triple-negative breast cancer: retrospective SEER-Medicare study of women age ≥65 years.
    Sieluk J; Yang L; Haiderali A; Huang M; Hirshfield KM
    Future Oncol; 2021 Jul; 17(20):2581-2592. PubMed ID: 33764155
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer.
    Celik A; Berg T; Jensen MB; Jakobsen E; Nielsen HM; Kümler I; Glavicic V; Jensen JD; Knoop A
    Breast Cancer (Auckl); 2023; 17():11782234231203292. PubMed ID: 37810797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple-negative breast cancer.
    Brezden-Masley C; Fathers KE; Coombes ME; Pourmirza B; Xue C; Jerzak KJ
    Cancer Med; 2020 Oct; 9(20):7548-7557. PubMed ID: 32862501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggressive Subsets of Metastatic Triple Negative Breast Cancer.
    Singh J; Asad S; Zhang Y; Nock W; Adams E; Damicis A; Ramaswamy B; Williams N; Parsons HA; Adalsteinsson VA; Winer EP; Lin NU; Partridge AH; Overmoyer B; Stover DG
    Clin Breast Cancer; 2020 Feb; 20(1):e20-e26. PubMed ID: 31631016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.
    Zhang J; Wang Z; Hu X; Wang B; Wang L; Yang W; Liu Y; Liu G; Di G; Hu Z; Wu J; Shao Z
    Int J Cancer; 2015 Jan; 136(1):204-11. PubMed ID: 24824628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and healthcare resource utilization for triple negative breast cancer in the Brazilian private healthcare system: a database study.
    Carlos Souto Maior Borba MA; de Mendonça Batista P; Falcão Almeida M; do Carmo Rego MA; Brandão Serra F; Barbour Oliveira JC; Nakajima K; Silva Julian G; Amorim G
    Sci Rep; 2023 Sep; 13(1):15785. PubMed ID: 37737435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.